menu search

PASG / Passage Bio, Inc. (PASG) CEO Edgar Cale on Q2 2022 Results - Earnings Call Transcript

Passage Bio, Inc. (PASG) CEO Edgar Cale on Q2 2022 Results - Earnings Call Transcript
Passage Bio, Inc. (NASDAQ:PASG ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Stuart Henderson - VP of Corporate Development and IR Edgar Cale - Interim CEO Simona King - CFO Mark Forman - Chief Medical Officer Conference Call Participants Brendan Smith - Cowen Neena Bitritto-Garg - Citi Alex Nackenoff - Raymond James Laura Chico - Wedbush Operator Good morning and welcome to the Passage Bio Second Quarter 2022 Financial and Operating Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company's request. Read More
Posted: Aug 6 2022, 10:50
Author Name: Seeking Alpha
Views: 110160

PASG News  

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

By GlobeNewsWire
April 17, 2023

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing tr more_horizontal

Passage Bio, Inc. (PASG) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 6, 2023

Passage Bio, Inc. (PASG) Q4 2022 Earnings Call Transcript

Passage Bio, Inc. (NASDAQ:PASG ) Q4 2022 Earnings Conference Call March 6, 2023 8:30 AM ET Company Participants Stuart Henderson - Vice President, Cor more_horizontal

Passage Bio Undervalued On Price, Long-Term Gene Therapy Prospects

By Seeking Alpha
February 28, 2023

Passage Bio Undervalued On Price, Long-Term Gene Therapy Prospects

Passage Bio's most advanced gene therapy reported good early Phase 1 data. Over $200 million in cash should provide funding until more data is availab more_horizontal

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

By GlobeNewsWire
February 27, 2023

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing tra more_horizontal

Passage Bio, Inc. (PASG) CEO Edgar Cale on Q2 2022 Results - Earnings Call Transcript

By Seeking Alpha
August 6, 2022

Passage Bio, Inc. (PASG) CEO Edgar Cale on Q2 2022 Results - Earnings Call Transcript

Passage Bio, Inc. (NASDAQ:PASG ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Stuart Henderson - VP of Corporate De more_horizontal

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 3, 2022

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript more_horizontal

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 3, 2022

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript more_horizontal

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 3, 2022

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript more_horizontal


Search within

Pages Search Results: